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Abstract
Background: Nanoparticles possess several advantages as a carrier system for intracellular delivery of therapeutic
agents. Rapamycin is an immunosuppressive agent which also exhibits marked antiproliferative properties. We
investigated whether rapamycin-loaded nanoparticles(NPs) can reduce neointima formation in a rat model of vein
graft disease.
Methods: Poly(lactic-co-glycolic acid) (PLGA) NPs containing rapamycin was prepared using an oil/water solvent
evaporation technique. Nanoparticle size and morphology were determined by dynamic light scattering
methodology and electron microscopy. In vitro cytotoxicity of blank, rapamycin-loaded PLGA (RPLGA) NPs was
studied using MTT Assay. Excised rat jugular vein was treated ex vivo with blank-NPs, or rapamycin-loaded NPs,
then interposed back into the carotid artery position using a cuff technique. Grafts were harvested at 21 days and
underwent morphometric analysis as well as immunohistochemical analysis.
Results: Rapamycin was efficiently loaded in PLGA nanoparticles with an encapsulation efficiency was 87.6%. The
average diameter of NPs was 180.3 nm. The NPs-containing rapamycin at 1 ng/ml significantly inhibited vascular
smooth muscular cells proliferation. Measurement of rapamycin levels in vein grafts shown that the concentration
of rapamycin in vein grafts at 3 weeks after grafting were 0.9 ± 0.1 μg/g. In grafted veins without treatment
intima-media thickness was 300.4 ±181.5 μm after grafting 21 days. Whereas, Veins treated with rapamycin-loaded
NPs showed a reduction of intimal-media thickness of 150.2 ± 62.5 μm (p = 0.001). CD-31 staining was used to
measure luminal endothelial coverage in grafts and indicated a high level of endothelialization in 21 days vein
grafts with no significant effect of blank or rapamycin-loaded NPs group.
Conclusions: We conclude that sustained-release rapamycin from rapymycin loaded NPs inhibits vein graft
thickening without affecting the reendothelialization in rat carotid vein-to-artery interposition grafts and this may
be a promising therapy for the treatment of vein graft disease.
Background
Surgical bypass via autologous vein remains an evi-
dence-based treatment of choice for selected patients
with coronary occlusive disease or infra-inguinal lower
extremity. However, contemporary data shows that
almost 60% of lower extremity vein bypass grafts
develop occlusive lesions or fail within a year [1], and
almost half of cardiac bypass patients will lose (≥ 75%
stenosis) a vein graft within a year [2]. Neointimal
hyperplasia, which develops immediately after grafting,
is the most important early change of the grafted vein.
Although not solely responsible for the graft failure, this
neointimal process is to be regarded as the guiding
track easing the development of fatal sclerotic changes
[3] With the exception of aggressive lipid lowering, [4]
no therapy has been shown to improve long-term vein
graft patency in clinical studies. Earlier experimental
studies such as placement of external porous dacron
stents [5] or perivascular application of decoy oligonu-
cleotides [1,2] have failed to translate into clinical bene-
fits because of early graft thrombosis and poor efficacy,
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shown that immersion of vein grafts in rapamycin solu-
tion immediately before grafting inhibits neointima for-
mation in porcine vein grafts; however, this effect is not
sustained.
Nanoparticles possess several advantages as a carrier
system for intracellular delivery of therapeutic agents.
These advantages include their subcellular size, good
suspensibility, an easy penetration into the vessel wall
without causing trauma, and the capacity for sustained
intracytoplasmic release [7,8 ] .T h e r e f o r e ,w eh y p o t h e -
sized that rapamycin-loaded nanoparticles (NPs) could
be an innovative therapeutic strategy for preventing vein
graft failure. In this study, we have explored the efficacy
of NPs as an intracellular ex vivo delivery system to the
excised vein, and whether these NPs suppressed vein
graft neointima formation in vivo. To our knowledge,
however, no prior studies have examined whether rapa-
mycin-loaded PLGA (RPLGA) NPs are useful as thera-
peutic strategy for preventing vein graft failure.
Methods
Materials for nanoparticle preparation
Rapamycin was obtained from Sigma, St. Louis, MO,
USA. Polyvinyl alcohol (PVA) 87-89% hydrolyzed, MW
31,000-50,000 was purchased from Advanced Technol-
ogy & Industrial Co. Ltd, Hong Kong, China. Poly(lac-
tic-co-glycolic acid) (PLGA) copolymer, monomer ratio
50:50, MW 20000 was purchased from Dai Gang Biol-
ogy, Shandong, China.
Preparation of PLGA NPs
PLGA NPs containing rapamycin was prepared using an
oil/water solvent evaporation technique based on a sin-
gle emulsion method [9]. Briefly, rapamycin was added
to PLGA solution in Dichloromethane. The resulting
solution was emulsified in 20 mL of 1% w/v PVA solu-
tion in PBS using a magnetic stirrer (Model 50-
HI190M-1 Sciencelab. Inc. Houston, Texas. USA) and
ultrasound probe 250W for 4 min, then the organic sol-
vent was removed from the final emulsion by evapora-
tion. The nanoparticle suspension was filtered through a
0.45 μm microporous membrane. Blank nanoparticles
were also prepared by the same method without adding
rapamycin at any stage of the preparation. The PLGA
nanoparticles were stored at -4°C for further studies.
Characterization of RPLGA NPs
Nanoparticle size and size distribution were determined
by Dynamic Light Scattering methodology using Zetasi-
zer (Model 3000 Malvern Instruments Worcestershire,
United Kingdom). The analysis was performed at a scat-
tering angle of 90 and at a temperature of 25°C using
sample appropriately diluted 20 times with filtered
distilled water (0.22 μm GV, Millipore, Ireland). The
morphology of the nanoparticles was examined using
transmission electron microscopy(TEM). A drop of the
nanoparticle suspension was transferred onto a small
metal cylinder. After drying, the sample was transferred
in the sample holder of a Jeol JEM-1010 electron micro-
scope(Tokyo, Japan).
Measurement of Encapsulation Efficiency
Encapsulation efficiency was performed using dialysis
bag diffusion technique. RPLGA NP samples (6 ml),
enclosed in dialysis bags (cellulose membrane, mw cut-
off 12400, Sigma), were incubated in 120 ml 5% sodium
lauryl sulphate (SLS) at 37°C under 300 r/min agitation
in a water bath for 8 h in order to release free dissolved
drug. The amount of rapamycin in incubation medium
was estimated by spectrophotometry based on the UV
absorbance at 277 nm, and the entrapment efficiency
was calculated by the equation:
Entrapment efﬁciency (%) = (1 − Free dissolved drug/Total drug content) × 100%
Study of the in vitro release of the rapamycin from the
RPLGA NPs
In vitro release studies were also carried out using dialy-
sis bag diffusion technique [10]. At predetermined time
intervals, 500 μl samples from SLS were withdrawn from
the incubation medium and analyzed for rapamycin with
spectrophotometry as described above. After sampling,
the incubation medium was replaced by fresh 5% SLS. A
control experiment to determine the release behavior of
the free drug was also performed. Rapamycin was dis-
solved in 5% SLS (13.95 μg/ml) and 5 ml of this solution
was enclosed in a dialysis bag and was immersed in 100
ml 5% SLS, 37°C. Then, the procedure described above
for the nanoparticle samples was followed.
Cellular Uptake and Antiproliferative Effect of RPLGA NPs
The vascular smooth muscular cells (VSMCs) were
incubated in the growth medium containing RPLGA
NPs (the rapamycin concentration: 50 ug/ml) for 1
hour. The cells were then washed with PBS and centri-
fuged for 8 min with 3000 rpm. The centrifugal cell
were fixed in 2% glutaraldehyde dissolved in 0.15M
phosphate buffer at pH 7.2 for 1 h, followed by post-
fixation in 1% osmium tetroxide dissolved in 0.9%
sodium chloride for 1 h. Fixed material was stained in
bloc in 0.5% aqueous uranyl acetate overnight. After this
procedure, the samples were dehydrated in graded acet-
one series, and embedded in Araldite resin. Ultrathin
sections (70 nm) were obtained using a diamond knife
in an LKB ultramicrotome, placed on 200-mesh copper
grids and double-stained by uranyl acetate and lead
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transmission electron microscope, operating at 80 kV.
In vitro cytotoxicity of blank, RPLGA NPs, and free
rapamycin were investigated using the primary VSMCs
culture. NPs were prepared under aseptic conditions.
Rapamycin was dissolved in 96% ethanol. To obtain dif-
ferent test concentrations, several dilutions of nanoparti-
cle suspensions were prepared with DMEM culture
medium. Ethanol amounts used for dilution showed no
influence on the cell viability during the experiments.
VSMCs were seeded into 96-well microtiter plates
(Nunclon™, Nunc, Germany) at a density of 4000 cells/
well. After an incubation period of 24 h the culture
medium was replaced with fresh, rapamycin, blank NPs,
and RPLGA NPs culture medium. After an additional
incubation time of 24 h the culture medium was
replaced with fresh culture medium. After an additional
incubation time of 48 h the viability of the cells was
evaluated by the MTT assay (n = 7). MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
(Invitrogen, USA) was dissolved in phosphate buffered
saline at 5 mg/ml and 20 μl were added to each well
reaching a final concentration of 0.5 mg/ml. After an
incubation time of 4 h unreacted dye was removed by
aspiration, the purple formazan product was dissolved
in 200 μl/well dimethyl sulfoxide and quantitated by a
plate reader (Titertek Plus MS 212, ICN, Germany) at
wavelengths of 490 nm.
Experimental Animal Models
Male Sprague-Dawley rats (n = 25) (350 to 400 g; Slac
Laboratory Animal Shanghai China) were anesthetized
with an intraperitoneal injection of a 10% Chloral
Hydrate (0.05 mg/kg), then a midline neck incision was
made, and an approximately 1-cm segment of the lateral
branches of external jugular vein was dissected free; all
side branches were ligated. The vein segments were
gently flushed, and placed in 1 ml solution containing
either blank-NPs (n = 5), or RPLGA NPs containing
rapamycin at 50 μg/ml (n = 5) for 30 minutes at room
temperature. The operation was performed as described
previously [11,12]. In brief the treated vein segments
were interposed into ipsilateral carotid arteries (everted
over a cuff). Animals were killed with a lethal dose of
anesthesia on days 21. The vein grafts were harvested,
flushed with saline, and used for histopathologic studies.
The investigation conforms with the Guide for the
Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication No.
85-23, revised 1996)
Histopathologic Analysis
For histological analysis the animals underwent autopsy
on days 21 (n = 5 each). The grafts were perfusion fixed
with 4% phosphate-buffered formaldehyde via puncture
of the left ventricle as previously described [12]. The
interposed vein segments were cut out at the cuff ends
and fixed with 4% phosphate-buffered formaldehyde.
Consecutively the veins were formalin fixed and
embedded in paraffin. Sections of 4 μmt h i c k n e s sw e r e
stained by Hematoxylin and Eosin for measurement of
the intimal thickness. The measurements were done
using Digimizer 3.1.1.0 image analysis software (Med-
Calc Software, Belgium). For achieving reproducible
results, the cross sections of the veins were divided into
4 quadrants. In each quadrant 3 measurements were
performed. The median value of all measurements was
regarded as representative for the intimal-median
thickness.
Evaluation of endothelial coverage within grafts was
achieved using an immunohistochemistry stain for CD-
31 as previously described. CD-31 antibody was
obtained from Santa Cruz Biotechnology, USA. Reen-
dothelialization was calculated as the percentage of
luminal surface covered by CD31-positive cells 3 weeks
after operation. Endothelial coverage was calculated as
an average score over 4 sections per graft.
Measurement of Rapamycin Levels
To determine vein graft drug uptake and retention, vein
grafts were removed at different time points after
administration of NPs. Rapamycin levels were measured
by high-performance liquid chromatography as pre-
viously described [13]. Briefly, whole-blood samples
(1 mL) or homogenized vein graft tissue were treated
with precipitation reagent (methyl tert-butyl ether:I-
chloroethane:methanol, 45:45:10) plus internal standard
solution (32-0-desmethoxysirolimus) followed by C18
solid-phase extraction. UV detection of the absorbance
peaks was performed at 278 nm, and values were
expressed as micrograms per gram of dry tissue.
Statistical analysis
The SPSS™ for Windows statistical software package
(SPSS 17 for Windows, SPSS Inc., Chicago, IL, USA)
was used for analysis. The value of MTT and intimal-
median thickness is given as median ± 2SE. Compari-
sons of reendothelialization and histological measure-
ments of the intimal-median thickness were made by
the two tailed, unpaired Student’s t test. Results were
considered statistically significant at p values of less
than 0.05.
Results
Characterization of RPLGA nanoparticles
Rapamycin was efficiently loaded in PLGA nanoparticles
reaching a loading capacity of 23 ug of drug to 1 mg of
polymer and an encapsulation efficiency of 87.6%.
Zou et al. Journal of Cardiothoracic Surgery 2011, 6:69
http://www.cardiothoracicsurgery.org/content/6/1/69
Page 3 of 8Dynamic light scattering analysis revealed an average
diameter of 180.3 nm (particle size range of 100-450
nm) for nanoparticles(Figure 1A). TEM showed a sphe-
rical shape for RPLGA nanoparticles (Figure 1B). The
diameter of nanoparticles measured from TEM pictures
was in the range of 100-300 nm, which was in agree-
ment with the results of light scattering measurements.
In vitro release of the rapamycin from the RPLGA
nanoparticles
An analysis of the in vitro drug release kinetics from
rapamycin loaded PLGA nanoparticles showed an early
burst of drug release, approximately 27% of the total
amount of drug, was observed on day 1, followed by
sustained release that lasted for 21 days. During this
period 80.2% of the drug was released (Figure 1D).
In Vitro Cell Uptake and Antiproliferative Effect of RPLGA
NPs
TEM of the cellular cross sections revealed the intracellu-
lar localization of NPs after 1 h of incubation (Figure 1C).
The MTT test served as an assay for proliferation and
cell viability by measuring the mitochondrial activity of
cells. The RPLGA NPs at 1 ng/ml significantly inhibited
Figure 1 Characterization and in vitro release of the rapamycin from the RPLGA nanoparticles. A, Dynamic light scattering analysis for
nanoparticles. B, Transmission electron micrograh RPLGA NPs. Bar represents 1 μm. C, Transmission electron microscopic picture of cross-section
of VSMCs incubated with NP for 1 hour. Arrows indicate NP in the cytoplasm. Scale bar = 1 μm. D, In vitro release profile of rapamycin from
RPLGA NPs. The percentage of rapamycin released was plotted against time.
Zou et al. Journal of Cardiothoracic Surgery 2011, 6:69
http://www.cardiothoracicsurgery.org/content/6/1/69
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0.01). The effect of inhibiton was similar to that of free
drug at 10 ng/ml(78.5 ± 5.74 vs. 79.1 ± 4.82; P = 0.85
Figure 2). There was non-antiproliferative character of
unloaded nanoparticles prepared from PLGA(97 ± 6.79
vs. 100 ± 3.01; P = 0.35).
Rapamycin Pharmacokinetics
Measurement of rapamycin levels in vein grafts demon-
strated the presence of drug in vein grafts at 0 days
(after the vein being immersed in rapamycin-loaded NPs
solution), 1 weeks and 3 weeks after grafting (n = 5)
(Figure 3). The concentrations of rapamycin in vein
grafts at 0 days, 1 weeks and 3 weeks after grafting were
5.4 ± 0.9 μg/g, 1.3 ± 0.2 μg/g and 0.9 ± 0.1 μg/g respec-
tively. Rapamycin was not detected with high-perfor-
mance liquid chromatography in whole-blood samples
of any experimental animal, 1 week after grafting.
Effects of RPLGA NPs on Vein Graft Failure in rats
The autologous interposition jugular vein graft was
explanted and examined 21 days. Figure 4 demonstrates
intima-media thickening at 21 days after implantation of
the vein into the arterial circulation. The intima and
media are measured together as the rat jugular vein has
no well-defined boundary between the two. In grafted
veins without treatment (controls, n = 5 at each point of
time) intima-media thickness was 300.4 ±181.5 μm after
21 days. Veins treated with rapamycin loaded NPs (n =
5 at each point of time) showed a reduction of intimal-
media thickness with 150.2 ±62.5 μm 21 days (p < 0.001
vs controls). Figure 1D demonstrates quantitative analy-
sis of remodeling in this model, with increased thickness
of the vein graft intima-media at 21 days.
CD-31 staining (Figure 1C) was used to measure lumi-
nal endothelial coverage in grafts and indicated a high
level of endothelialization in 21 days with no significant
difference between control and RPLGA NPs group
(88.2% ± 7.1% vs. 86.4% ± 7.5%; P = 0.8) (Figure 1E).
Discussion
In this study, we have demonstrated for the first time
that PLGA NPs is an excellent system for intracellular
delivery of rapamycin in excised veins. This NPs system
is bioabsorbable polymer with a long history of safe use
in medical applications. The RPLGA NPs was endocy-
tosed rapidly by VSMCs. After cellular uptake of NPs,
they slowly release encapsulated drugs into the cyto-
plasm whereas PLGA gets hydrolyzed, resulting in an
intracellular drug delivery and thereby significantly inhi-
biting VSMCs proliferation. An important finding was,
long-term release of rapamycin in the vein until day 21
after grafting which suggests that RPLGA NPs delivery
system may be applied to human beings clinically. The
bio-absorption time of PLGA in the body can be con-
trolled by changing material make-up of PLGA, thus the
function of the intracellular drug delivery system can be
modified. Therefore, this NPs-mediated drug delivery
system works as an excellent ex vivo delivery of rapamy-
cin for the excised vein to prevent vein graft failure.
Rapamycin is a macrocyclic, lipophilic lactone with
immunosuppressive antibiotic activity derived from the
actinomycete streptomyces hygroscopicus. The well-
established effect of rapamycin are the inhibition of the
progression of the cells from the G1 to the S phase within
the mitotic cycle and VSMCs migration [14-16]. The drug
is clinically used in transplantation medicine and as a coat-
ing of coronary artery stents. Rapamycin-eluting stents sig-
nificantly reduce the incidence of restenosis and late loss
of arterial luminal diameter [17]. Schachner and colleagues
[18] have shown in an experimental study that rapamycin
could inhibit the development of neointimal hyperplasia in
a mouse autologous graft transplantation model (vein to
artery), with a peri-paravascular application of rapamycin
applied locally in pluronic gel. With the use of pluronic
Figure 2 In vitro effects of RPLGA NPs on proliferation of
SMCs. Data represents mean ± 1SEM (n = 6 each) and percentage
changes from control (100%). *P < 0.01 vs control.
Figure 3 Rapamycin Pharmacokinetics. Graph showing vein graft
rapamycin levels at 0, 7 and 21 days after grafting. Bars represent
mean ± 1SEM.
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reached but one disadvantage of this method, however, is
the limited release time of the gel. As an example, Fulton
and colleagues [19] found that after 5 days, 80% of anti-
sense oligonucleotides to proliferating cell nuclear antigen
(PCNA) were released from pluronic gel.
In a recently published study Walpotha and colleagues
shown a reduction of neointimal hyperplasia with a high
dose of systemic rapamycin treatment (3 mg/Kg) either
after 30 or 60 days in a rat infrarenal graft model. This
dosage was similar to the one used in the transplanta-
tion model. However, they observed drug related side
effects as well as a catabolic metabolism with lack of
weight increase, which would limit the clinic use of this
method [20].
In our experiment we found that the proliferation of
VSMCs was inhibited significantly by RPLGA NPs when
the concentration of rapamycin was 1 ng/ml. The
concentration was one-tenth of free drug. This shows
that the PLGA nanopariticle increases the effects of
rapamycin, which may be related to nanoparticles ability
to increase the drug solubility and cell membrane pene-
tration. At the same time, the rapamycin-loaded NPs
can penetrate into the vessel wall easily ex vivo and sus-
tained release the drug at least 3 weeks, so the early
stage intimal hyperplasia of vein graft was inhibited
significently.
The study of Thirumaran and colleagues [21] have
shown that periadventitial application of rapamycin-elut-
ing polyvinyl alcohol microspheres to porcine saphenous
vein-to-carotid artery interposition grafts inhibited vas-
cular smooth muscle cell proliferation in 1-week grafts.
The inhibition of vein graft thickening was not sus-
tained; however, there was no therapeutic benefit evi-
dent in 12-week grafts. It may be related to the shorter
time of drug retention (rapamycin was not detected at
Figure 4 Effects of ex vivo treatment with rapamycin-loaded NPs on vein graft neointima formation and reendothelializaton in rats
at 21 days. A and B, Vein graft sections of animals treated with PLGA NPs (left, control) and with RPLGA-NPs (right, treated), stained with
Hematoxylin and Eosin. D, Bar graphs represent the morphometric analysis of vein graft sections about the inhibition of hyperplasia (intima-
media thickness) in different treatment groups. Quantitative data derived from 3 vein graft sections at different levels from each animal in
each group. *P < 0.001 for treated (n = 5) versus control (n = 5) groups. C, Endothelial coverage within grafts was achieved using an
immunohistochemistry stain for CD-31. E, Bar graphs represent no significant effect of control or RPLGA-NPs group P = 0.8. Bars represent
mean ± 1SEM.
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biodegradable PLA-CL film applied externally can inhi-
bit neointimal hyperplasia of anastomotic sites of arterial
and vein grafts in a canine model. By the end of fourth
week, the film had been completely absorbed; relatively
drug retention time was also less. However, in our study
the rapamycin was detected after 21 days, and the con-
centration was relatively higher, similar observations
were made by Reddy et al wherein they have used cross-
linked gel-like polymeric NPs for delivery system of rapa-
mycin in injured artery [23]. Because RPLGA NPs can
easily penetrate into the vessel wall and their sustained
release of rapamycin into cell cytoplasm, the inhibition to
the intimal hyperplasia of vein graft would maintain for a
longer durations. In our study, the rapamycin level in the
vein graft was 5.4 μg / ga f t e rb e i n gi m m e r s e d ,a n dt h e
level decreased during the first week but remained con-
stant thereafter for the next 2 weeks. It is possible that
the NPs localized in the intimal layer might have washed
away with blood flow and the NPs localized in the adven-
titia diffused into the surrounding tissue after the initial
localization, resulting in the initial decrease in drug level.
However, the NPs localized in the vein graft were
retained and able to maintain the drug level.
Because rapamycin has been reported to suppress the
adhesion of endothelial progenitor cells and their differ-
entiation into endothelium [24]. The biggest drawback
of coated stent is adversely influencing the process of
reendothelialization, thereby causing acute thrombosis.
However, we have observed that the RPLGA NPs did
not affect reendothelialization of the vein graft. One of
the main reasons that stented arteries do not undergo
reendothelialization very well is because of their direct
contact with the intimal layer of the drug used to coat
the stent, consequently either inhibiting the proliferation
of endothelial cells or preventing adhesion and differen-
tiation of circulating endothelial progenitor cells to the
injured endothelium [25]. The drug localized in the vein
graft was probably not interfering in the process, allow-
ing vascular repair to occur by the natural mechanism.
Conclusions
In conclusion, sustained-release of rapamycin from
RPLGA NPs inhibits vein graft thickening in rat carotid
vein-to-artery interposition grafts 3 weeks, this does not
affect the reendothelialization of the vein graft. There-
fore, this NPs-mediated drug delivery system works as
an excellent ex-vivo delivery of rapamycin for the
excised vein to prevent vein graft failure.
Acknowledgements
The authors wish to express their appreciation to Liu Jianping, PhD, for her
superb technical assistance during the preparation and characterization of
RPLGA NPs.
Author details
1Department of General Surgery, the First Affiliated Hospital of Nanjing
Medical University, Nanjng, Jiangsu province, China.
2Division of Vascular
Surgery, Department of General Surgery, the First Affiliated Hospital of
Nanjing Medical University, Nanjng, Jiangsu province, China.
Authors’ contributions
JZ designed study, analyzed and interpreted the data, and prepared
manuscript. XZ contributed to study design, data analysis and interpretation,
and preparation of manuscript. HY contributed to data collection, and
preparation of manuscript. HM contributed to interpretation of data and
manuscript preparation. YZ contributed to study design, and preparation of
manuscript. SW contributed to study design, analyzed and interpretation of
data and manuscript preparation. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 October 2010 Accepted: 12 May 2011
Published: 12 May 2011
References
1. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H,
Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH,
Berman SS, PREVENT III Investigators: Results of PREVENT III: a multicenter,
randomized trial of edifoligide for the prevention of vein graft failure in
lower extremity bypass surgery. J Vasc Surg 2006, 43:742-751.
2. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr,
Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM,
Kouchoukos NT, PREVENT IV Investigators: Efficacy and safety of
edifoligide, an E2F transcription factor decoy, for prevention of vein
graft failure following coronary artery bypass graft surgery: PREVENT IV:
a randomized controlled trial. JAMA 2005, 294:2446-2454.
3. Schwartz SM, deBlois D, O’Brien ER: The intima soil for atherosclerosis and
restenosis. Circ Res 1995, 77:445-465.
4. Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M,
Forman SA, Forrester JS, Geller NL, Gobel FL, Herd JA, Hoogwerf BJ,
Rosenberg Y: Aggressive cholesterol lowering delays saphenous vein
graft atherosclerosis in women, the elderly, and patients with associated
risk factors. NHLBI post coronary artery bypass graft clinical trial Post
CABG Trial Investigators. Circulation 1999, 99:3241-3247.
5. Murphy GJ, Newby AC, Jeremy JY, Baumbach A, Angelini GD: A
randomized trial of an external Dacron sheath for the prevention of
vein graft disease: the Extent Study. J Thorac Cardiovasc Surg 2007,
134:504-505.
6. Murphy GJ, Johnson TW, Chamberlain MH, Rizvi SI, Wyatt M, George SJ,
Angelini GD, Karsch KR, Oberhoff M, Newby AC: Short-and long-term
effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in
experimental porcine vein grafts. Cardiovas Res 2007, 73:607-617.
7. Rejman J, Oberle V, Zuhorn IS, Hoekstra D: Size-dependent internalization
of particles via the pathways of clathrin- and caveolae-mediated
endocytosis. Biochem J 2004, 377:159-169.
8. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V: Rapid endo-
lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles:
implications for drug and gene delivery. Faseb J 2002, 16:1217-1226.
9. Haddadi A, Elamanchili P, Lavasanifar A, Das S, Shapiro J, Samuel J: Delivery
of rapamycin by PLGA nanoparticles enhances its suppressive activity
on dendritic cells. J Biomed Mater Res A 2008, 84:885-898.
10. Leroueil-Le Verger M, Fluckiger L, Kim YI, Hoffman M, Maincent P:
Preparation and characterization of nanoparticles containing an
antihypertensive agent. Eur J Pharm Biopharm 1998, 46:137-143.
11. Schachner T, Zou Y, Oberhuber A, Mairinger T, Tzankov A, Laufer G, Ott H,
Bonatti J: Perivascular application of C-type natriuretic peptide
attenuates neointimal hyperplasia in experimental vein grafts. Eur J
Cardiothorac Surg 2004, 25:585-590.
12. Zou Y, Dietrich H, Hu Y, Metzler B, Wick G, Xu Q: Mouse model of venous
bypass graft disease. Am J Pathol 1998, 153:1301-1310.
13. Holt DW, Lee T, Johnston A: Measurement of sirolimus in whole blood
using high-performance liquid chromatography with ultraviolet
detection. Clin Therap 2000, 22:B38-B48.
Zou et al. Journal of Cardiothoracic Surgery 2011, 6:69
http://www.cardiothoracicsurgery.org/content/6/1/69
Page 7 of 814. Moon JI, Kim YS, Kim MS, Kim EH, Kim HJ, Kim SI, Park K: Effect of
cyclosporine, mycophenolic acid and rapamycin on the proliferation of
rat aortic vascular smooth muscle cells. Transplant Proc 2000,
32:2026-2027.
15. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR: Rapamycin
inhibits smooth muscle cell migration. J Clin Invest 1996, 98:2277-2283.
16. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE: Role for p27kip1
in vascular smooth muscle cell migration. Circulation 2001, 103:2967-2972.
17. Hill RA, Dundar Y, Bakhai A, Dickson R, Walley T: Drug-eluting stents: an
early systematic review to inform policy. Eur Heart J 2004, 25:902-919.
18. Schachner T, Zou Y, Oberhuber A, Tzankov A, Mairinger T, Laufer G,
Bonatti JO: Local application of rapamycin inhibits neointimal
hyperplasia in experimental vein grafts. Ann Thorac Surg 2004,
77:1580-1585.
19. Fulton GJ, Davies MG, Barber L, Svendsen E, Hagen PO: Locally applied
antisense oligonucleotide to proliferating cell nuclear antigen inhibits
intimal thickening in experimental vein grafts. Ann Vasc Surg 1998,
12:412-417.
20. Walpotha BH, Pavliceka M, Celika B, Nicolaus B, Schaffner T, Althaus U,
Hess OM, Carrel T, Morris RE: Prevention of neointimal proliferation by
immunosuppression in synthetic vascular grafts. Eur J Cardiothorac Surg
2001, 19:487-492.
21. Rajathurai T, Rizvi SI, Lin H, Angelini GD, Newby AC, Murphy GJ:
Periadventitial rapamycin-eluting microbeads promote vein graft disease
in long-term pig vein-into-artery interposition grafts. Circ Cardiovasc
Interv 2010, 3:157-165.
22. Kawatsu S, Katsuhiko O, Saiki Y, Tabata Y, Tabayashi K: External application
of rapamycin-eluting film at anastomotic sites inhibits neointimal
hyperplasia in a canine model. Ann Thorac Surg 2007, 84:560-567.
23. Reddy MK, Vasir JK, Sahoo SK, Jain TK, Yallapu MM, Labhasetwar V:
Inhibition of apoptosis through localized delivery of rapamycin-loaded
nanoparticles prevented neointimal hyperplasia and reendothelialized
injured artery. Circ Cardiovasc Interv 2008, 1:209-216.
24. Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK,
Fiedler W: Rapamycin inhibits proliferation and differentiation of human
endothelial progenitor cells in vitro. Exp Cell Res 2004, 300:65-71.
25. Cejna M, Virmani R, Jones R, Bergmeister H, Losert U, Xu Z, Yang P,
Schoder M, Lammer J: Biocompatibility and performance of the Wallstent
and several covered stents in a sheep iliac artery model. J Vasc Interv
Radiol 2001, 12:351-358.
doi:10.1186/1749-8090-6-69
Cite this article as: Zou et al.: Rapamycin-loaded nanoparticles for
inhibition of neointimal hyperplasia in experimental vein grafts. Journal
of Cardiothoracic Surgery 2011 6:69.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zou et al. Journal of Cardiothoracic Surgery 2011, 6:69
http://www.cardiothoracicsurgery.org/content/6/1/69
Page 8 of 8